The NDC Directory contains information on active and certified finished and unfinished drugs submitted to FDA in structured product labeling (SPL) electronic listing files by labelers. NDC 0054-0188-13: Bottle of 30 Tablets 8 mg/2 mg are supplied as speckled-peach to peach, flat faced beveled edge tablets with product identification “54” [above] “375” on one side and plain on the other. Our NDC Lookup Tool is designed to simplify your search for comprehensive drug information. Whether you are a healthcare professional, researcher, or just curious about medications, our tool is tailored to meet your needs with speed and precision. DEA- Cl3-Buprenorphine-Naloxone 8-2MG 30 Tab by Hikma Pharma USA, Item No. DEA-CL3-DEA504997, A-CL3-, NDC No.: 00054-0189-13, 00054-189-13, 0005418913, 00054018913, 0189-13, 018913 UPC No. 3-00540-18913-6, 300540-189136, 300540189136, Category:DEA-CL3-, Controlled Drugs Drug Classification: Narcotic Analgesics Drug Class: Drug Class: 28081200. The National Acquisition Center Contract Catalog Search Tool now allows your facility to browse MedSurg and Pharmaceutical products and services available under Federal Supply Service contracts. The search tool allows the user to locate items using a variety of search criteria, including item description, special item number (SIN) and contract number. Item detail tab contains detailed. Is this product currently listed with the FDA? Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Hikma Pharmaceuticals Usa Inc. on June 27, 2014. The current certification is valid through December 31, 2027. Buprenorphine and Naloxone Sublingual Tablets are indicated for the maintenance treatment of opioid dependence. The current wholesale acquisition cost for Buprenorphine And Naloxone (NDC 0054-0189-13) is $0.63786 per EA. This benchmark price is based on the National Average Drug Acquisition Cost (NADAC) and has been effective since Aug 19, 2026. These highlights do not include all the information needed to use BUPRENORPHINE and NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE and NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE and NALOXONE sublingual tablets, for sublingual administration CIII Initial U.S. Approval: 2002. This medication is used to help relieve severe ongoing pain (such as due to arthritis, chronic back pain). Buprenorphine belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.